212 related articles for article (PubMed ID: 23456389)
1. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
[TBL] [Abstract][Full Text] [Related]
2. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
[TBL] [Abstract][Full Text] [Related]
3. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
[TBL] [Abstract][Full Text] [Related]
4. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
[TBL] [Abstract][Full Text] [Related]
5. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
6. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.
Gaedcke J; Grade M; Jung K; Schirmer M; Jo P; Obermeyer C; Wolff HA; Herrmann MK; Beissbarth T; Becker H; Ried T; Ghadimi M
Radiother Oncol; 2010 Jan; 94(1):76-81. PubMed ID: 19913317
[TBL] [Abstract][Full Text] [Related]
7. KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.
Boissière-Michot F; Lopez-Crapez E; Frugier H; Berthe ML; Ho-Pun-Cheung A; Assenat E; Maudelonde T; Lamy PJ; Bibeau F
Mod Pathol; 2012 May; 25(5):731-9. PubMed ID: 22282307
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis.
Clancy C; Burke JP; Coffey JC
Surg Oncol; 2013 Jun; 22(2):105-11. PubMed ID: 23473635
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
[TBL] [Abstract][Full Text] [Related]
10. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
Russo AL; Ryan DP; Borger DR; Wo JY; Szymonifka J; Liang WY; Kwak EL; Blaszkowsky LS; Clark JW; Allen JN; Zhu AX; Berger DL; Cusack JC; Mamon HJ; Haigis KM; Hong TS
J Gastrointest Cancer; 2014 Mar; 45(1):34-9. PubMed ID: 24006244
[TBL] [Abstract][Full Text] [Related]
11. KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery.
Lee JW; Lee JH; Shim BY; Kim SH; Chung MJ; Kye BH; Kim HJ; Cho HM; Jang HS
Medicine (Baltimore); 2015 Aug; 94(31):e1284. PubMed ID: 26252300
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
Jo P; König A; Schirmer M; Kitz J; Conradi LC; Azizian A; Bernhardt M; Wolff HA; Grade M; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
PLoS One; 2016; 11(4):e0153278. PubMed ID: 27064574
[TBL] [Abstract][Full Text] [Related]
13. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery.
Derbel O; Wang Q; Desseigne F; Rivoire M; Meeus P; Peyrat P; Stella M; Martel-Lafay I; Lemaistre AI; de La Fouchardière C
BMC Cancer; 2013 Apr; 13():200. PubMed ID: 23617638
[TBL] [Abstract][Full Text] [Related]
14. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Yoon HH; Tougeron D; Shi Q; Alberts SR; Mahoney MR; Nelson GD; Nair SG; Thibodeau SN; Goldberg RM; Sargent DJ; Sinicrope FA;
Clin Cancer Res; 2014 Jun; 20(11):3033-43. PubMed ID: 24687927
[TBL] [Abstract][Full Text] [Related]
15. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
[TBL] [Abstract][Full Text] [Related]
16. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
[TBL] [Abstract][Full Text] [Related]
17. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
[TBL] [Abstract][Full Text] [Related]
18. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis and clinical correlation of metastatic colorectal cancer.
Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
